Who is sponsoring NCT04679584?

NCT04679584 is sponsored by University Hospital Schleswig-Holstein.

Is NCT04679584 still recruiting?

NCT04679584 is currently recruiting now. Last updated 22 December 2020.

Last reviewed 2020-12-22 · How we verify

NCT04679584: NAPKON-POP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVIDOM: Longterm Morbidity of SARS-CoV-2 Infection and COVID-19 Disease - Consequences for Health Status and Quality of Life

Recruiting now Last updated 22 December 2020

What this trial tests

trial testing Observation of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings in COVID-19 in 2,000 participants. Currently enrolling.

Timeline

16 November 2020

Primary endpoint
31 December 2021

31 December 2030

Quick facts

Lead sponsor	University Hospital Schleswig-Holstein
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	2,000
Start date	16 November 2020
Primary completion	31 December 2021
Estimated completion	31 December 2030
Sites	3 locations across Germany

Drugs / interventions tested

Observation of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

University Hospital Schleswig-Holstein

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

COVID-19 is a novel disease caused by SARS-CoV-2 that primarily affects the lungs but also various other organs of the body already in early stages of the disease. Due to the multiple organ involvements in the acute phase, it is conceivable that - in a significant proportion of patients - longterm sequels in various organ systems might occur, thereby impacting the individual's health status and quality of life; and posing a relevant burden to the resources of the health care system Assessment of SARS-CoV-2-longterm morbidity and sequels on the population level: In order to identify and treat these sequels in a timely fashion and to get a sense of the prevalence of such SARS-CoV-2 sequels on the population level, it is important to collect follow-up data and to comprehensively re-examine a population-representative sample of SARS-CoV-2 infected individuals. Within the COVIDOM study we will conduct deep clinical and biochemical phenotyping in population-representative samples in Germany. This will allow novel insights into disease pathogenesis and chronicity of virus infections.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Post-acute COVID-19 syndrome.
Nalbandian A, Sehgal K, Gupta A, Madhavan MV, et al · · 2021 · cited 3355× · PMID 33753937 · DOI 10.1038/s41591-021-01283-z
Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study.
Bahmer T, Borzikowsky C, Lieb W, Horn A, et al · · 2022 · cited 129× · PMID 35875815 · DOI 10.1016/j.eclinm.2022.101549
Fatigue and cognitive impairment after COVID-19: A prospective multicentre study.
Hartung TJ, Neumann C, Bahmer T, Chaplinskaya-Sobol I, et al · · 2022 · cited 120× · PMID 36133318 · DOI 10.1016/j.eclinm.2022.101651
The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics.
Schons M, Pilgram L, Reese JP, Stecher M, et al · · 2022 · cited 44× · PMID 35904671 · DOI 10.1007/s10654-022-00896-z
Predictors of non-recovery from fatigue and cognitive deficits after COVID-19: a prospective, longitudinal, population-based study.
Hartung TJ, Bahmer T, Chaplinskaya-Sobol I, Deckert J, et al · · 2024 · cited 40× · PMID 38333368 · DOI 10.1016/j.eclinm.2024.102456
Long-term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP).
Horn A, Krist L, Lieb W, Montellano FA, et al · · 2021 · cited 32× · PMID 34642875 · DOI 10.1007/s15010-021-01707-5
Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort.
Shi Y, Strobl R, Apfelbacher C, Bahmer T, et al · · 2023 · cited 10× · PMID 37231313 · DOI 10.1007/s15010-023-02043-6
Subdomains of Post-COVID Syndrome (PCS) - a population-based study.
Ballhausen-Lübcker S, Ruß AK, Lieb W, Schäfer A, et al · · 2025 · cited 3× · PMID 40859262 · DOI 10.1186/s12879-025-11368-6

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other University Hospital Schleswig-Holstein trials

Trials by the same sponsor.

NCT07591376 — A Reminder App to Improve Physical Activity During Radiotherapy for Lung Cancer - a Pre-study in Healthy Volunteers · NA · completed
NCT07286747 — Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT) · Phase 2 · recruiting
NCT07380815 — Physical Activity During Radiation Therapy for Lung Cancer · not yet recruiting
NCT07148336 — Identification of Chemotherapy-induced Peripheral Neuropathy · NA · not yet recruiting
NCT07444801 — Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04679584 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Schleswig-Holstein
Last refreshed: 22 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04679584.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing